ArticleDermatologie (Heidelberg, Germany)2025
[Bilateral carpal tunnel syndrome in a patient with malignant melanoma undergoing adjuvant pembrolizumab therapy].
Article in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are successfully used in multiple malignant diseases. Their spectrum of adverse effects includes dermatological, endocrinological, gastrointestinal, and hepatic toxicities, as well as rare neurological side effects affecting the central nervous system and more frequently the peripheral nervous system. Pre-existing neurological disorders may deteriorate. Bilateral carpal tunnel syndrome (CTS) rarely occurs. In the present case, an 83-year-old patient with stage IIIC malignant melanoma (MM) developed pain, swelling, and paresthesia in both hands after five adjuvant therapy cycles with pembrolizumab 200 mg. Following the diagnosis of bilateral CTS, pulse therapy with prednisolone was initiated and subsequently reduced to a maintenance dose of 20 mg orally. Despite the necessary escalation of ICI therapy to ipilimumab/nivolumab due to MM progression, CTS improved under concomitant prednisolone therapy and physiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.